世界中医药
文章摘要
引用本文:喻露1,阿依努尔1,杜泽慧1,冯莉1,杨四梅2.灯盏生脉胶囊对血管性认知功能障碍患者的疗效及部分机制[J].世界中医药,2019,(08):.  
灯盏生脉胶囊对血管性认知功能障碍患者的疗效及部分机制
Exploration on the Efficacy and Some Mechanisms of Dengzhan Shengmai Capsules in Vascular Cognitive Impairment
投稿时间:2019-01-26  
DOI:10.3969/j.issn.1673-7202.2019.08.039
中文关键词:  血管性认知功能障碍  灯盏生脉胶囊  中医证候积分  血管内皮功能  氧化应激
English Keywords:Vascular cognitive impairment  Dengzhan Shengmai Capsules  Integral of TCM Syndrome  Vascular endothelial function  Oxidative stress
基金项目:新疆兵团医药卫生科技攻关计划课题(2014BA03)
作者单位
喻露1,阿依努尔1,杜泽慧1,冯莉1,杨四梅2 1 新疆军区总医院干五科乌鲁木齐830000 2 新疆军区总医院输血科乌鲁木齐830000 
摘要点击次数: 555
全文下载次数: 534
中文摘要:
      目的:评估灯盏生脉胶囊对血管性认知功能障碍(VCI)的疗效,探讨其实现作用的可能机制。方法:选取2015年12月至2018年7月新疆军区总医院首诊为VCI的患者130例作为研究对象,按照随机数表法将其分为对照组和观察组,每组65例。对照组患者接受临床VCI患者常规西医治疗,观察组患者在对照组基础上加入灯盏生脉胶囊,持续治疗3个月后评估疗效。比较2组患者认知功能量表评分及中医证候积分、血管内皮功能指标[内皮素-1(ET-1)、一氧化氮(NO)]及氧化应激指标[超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)]的水平,药物不良反应发生情况的差异。结果:治疗后,观察组的MoCA评分值高于对照组,血管性痴呆的中医辨证量表(SDSVD)评分值低于对照组;智能衰退、反应迟钝、头晕耳鸣、纳呆等中医证候积分值低于对照组;血清中ET-1的水平低于对照组,NO的水平高于对照组;血清中SOD、GSH-Px的水平高于对照组,MDA的水平低于对照组,差异有统计学意义(P<005)。2组服药期间皮疹、腹泻便秘的发生率差异无统计学意义(P>005)。结论:灯盏生脉胶囊可有效改善VCI患者的认知功能且有良好的用药安全性,其作用机制可能与调节血管内皮功能、抗氧化应激等相关。
English Summary:
      To evaluate the effect of Dengzhan Shengmai Capsule on vascular cognitive impairment(VCI)and explore its possible mechanism.Methods:A total of 130 cases of VCI patients first diagnosed in our hospital during December 2015 to July 2018 were divided into control group and Dengzhan Shengmai Capsule group each with 65 cases by random number table method.Patients in control group were treated with routine western medicine treatment,those in the Dengzhan Shengmai Capsule group added Dengzhan Shengmai Capsule on the basis of control group.The curative effect was evaluated after 3 months of continuous treatment.The differences of cognitive function scale score,TCM syndrome score,vascular endothelial function indexes[Endothelin-1(ET-1)and nitric oxide(NO)],oxidative stress indexes[Superoxide dismutase(SOD),glutathione peroxidase(GSH-Px),malondialdehyde(MDA)] and adverse drug reactions between two groups were compared.Result:After treatment,score of MoCA in Dengzhan Shengmai Capsule group was higher than those in control group,while score of SDSVD in SDSVD group was lower than those in control group; scores of TCM syndromes such as mental decline,slow reaction,dizziness,tinnitus and dementia were lower than those in control group; serum content of ET-1 was lower than that in control group,NO was higher than that in control group; serum contents of SOD and GSH-Px in serum were higher than those in control group(P<005).There were no significant difference in the incidences of skin rash,diarrhea and constipation between two groups(P>005).Conclusion:Dengzhan Shengmai Capsules can effectively improve the cognitive function of VCI patients and has good drug safety.Its mechanism may be related to the regulation of vascular endothelial function and antioxidant stress.
查看全文  查看/发表评论  下载PDF阅读器